Skip to main content

Table 4 Comparison of the lab investigations between before and after treatment within each liver stiffness category

From: Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: a prospective longitudinal study

Variables

Liver stiffness

Before treatment

After treatment

Improvement %

p-value

AST (U/L)

 < 10 kPa

45.91 ± 3.12

24.40 ± 8.43

46.85%

0.0001*

10–15 kPa

56.24 ± 4.64

39.64 ± 2.83

29.52%

0.168

 > 15 kPa

61.49 ± 6.07

37.25 ± 7.47

39.42%

0.002*

ALT (U/L)

 < 10 kPa

51.54 ± 4.31

17.20 ± 9.80

66.63%

0.0001*

10–15 kPa

48.77 ± 9.36

32.19 ± 9.62

34.00%

0.161

 > 15 kPa

53.37 ± 4.57

26.41 ± 2.90

50.52%

0.001*

Albumin (g/dL)

 < 10 kPa

4.14 ± 0.43

4.13 ± 0.32

0.24%

0.827

10–15 kPa

3.92 ± 0.58

4.06 ± 0.30

 − 3.57%

0.397

 > 15 kPa

3.54 ± 0.67

3.75 ± 0.41

 − 5.93%

0.163

Bilirubin (mg/dL)

 < 10 kPa

0.72 ± 0.36

0.51 ± 0.36

29.17%

0.002*

10–15 kPa

0.78 ± 0.29

0.53 ± 0.14

32.05%

0.005*

 > 15 kPa

0.99 ± 0.38

0.81 ± 0.27

18.18%

0.174

INR

 < 10 kPa

1.06 ± 0.08

1.11 ± 0.10

 − 4.72%

0.002*

10–15 kPa

1.10 ± 0.17

1.41 ± 0.68

 − 28.18%

0.167

 > 15 kPa

1.24 ± 0.28

1.29 ± 0.22

 − 4.03%

0.484

PLTs/µL

 < 10 kPa

222,259 ± 65,665

277,833 ± 559,642

 − 25.00%

0.406

10–15 kPa

233,000 ± 64,647

248,363 ± 257,346

 − 6.59%

0.850

 > 15 kPa

164,406 ± 62,332

132,650 ± 54,319

19.32%

0.059

AFP (ng/mL)

 < 10 kPa

5.01 ± 3.20

3.38 ± 2.97

32.53%

0.004*

10–15 kPa

5.03 ± 2.96

4.25 ± 3.50

15.51%

0.547

 > 15 kPa

12.23 ± 2.86

8.48 ± 1.38

30.66%

0.168

FIB-4

 < 10 kPa

2.27 ± 1.41

1.54 ± 0.73

32.16%

0.001*

10–15 kPa

3.41 ± 3.09

2.76 ± 1.83

19.06%

0.491

 > 15 kPa

4.72 ± 2.30

3.81 ± 2.60

19.28%

0.206

  1. Data are expressed as mean ± standard deviation. p-value: probability value. *Significant (p < 0.05)